TICAR
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TICAR is a small-molecule injectable approved in 1976 for treatment of pelvic infections, colorectal cancer, lung cancer, HIV infection, and malnutrition. The mechanism of action is unknown based on available data. This legacy product represents a multi-indication injectable therapy with established clinical use across oncology and infectious disease.
LOE Approaching
LOE-approaching lifecycle indicates contracting team size; focus shifting to managed care and generic transition support rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of MG-K10 in Chronic Spontaneous Urticaria
Started Apr 2026
226 enrolled
Chronic Spontaneous Urticaria (CSU)
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
Started Mar 2026
400 enrolled
Chronic Spontaneous Urticaria
A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China
Started Mar 2026
3,485 enrolled
Chronic Urticaria
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
Started Feb 2026
344 enrolled
Chronic Spontaneous Urticaria (CSU)
A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
Started Jan 2026
350 enrolled
Chronic Spontaneous Urticaria
Worked on TICAR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.